A Contemporary Pathomechanistic Nosology of Inherited Lysosomal Disorders.

Eamon P McCarron, Nenad Blau, Emily R Eden, Frances M Platt, Johannes M Aerts, Simon A Jones, Carlos R Ferreira, Karolina M Stepien

Journal: Journal of inherited metabolic disease 2026;49(5):e70245

PMID: 42642022

Abstract

Lysosomal disorders (LDs) have traditionally been defined by intra-lysosomal substrate accumulation resulting from deficiencies of lysosomal enzymes or associated proteins. Advances in lysosomal biology have demonstrated that lysosomes function as central regulators of cellular signalling, membrane trafficking, autophagy, nutrient sensing, organelle communication and cellular homeostasis, expanding the spectrum of inherited disorders associated with lysosomal dysfunction beyond classical storage phenotypes. We developed a contemporary pathomechanistic nosology of inherited LDs through expert curation and targeted review of databases and published literature. Disorders were included when pathogenic variants resulted in lysosomal dysfunction as a major disease mechanism through defects affecting lysosomal degradation, membrane function, intracellular trafficking, biogenesis, autophagy-lysosome pathways or lysosome-related organelles. A total of 108 inherited lysosomal disorders caused by defects in 102 genes were identified and organised into 11 major disease categories. Neurologic and eye involvement were the most frequently affected organ-system categories, occurring in 80.6% and 68.5% of disorders, respectively. Digestive (including hepatosplenomegaly), dysmorphic, skeletal and haematological involvement occurred in 48.1%, 45.4%, 40.7% and 38.9% of disorders, respectively. Distinct phenotypic signatures were observed across disease categories despite substantial mechanistic overlap involving impaired autophagy, vesicular trafficking, lysosomal stress and altered organelle homeostasis. This proposed nosology extends disease classification beyond substrate accumulation alone and provides a biologically informed framework for disease classification, genomic interpretation, biomarker development, patient stratification and the development of mechanism-based therapies.

© 2026 SSIEM.

Address: Adult Inherited Metabolic Disorders, Sheffield National Health Service (NHS) Foundation Trust, Sheffield, UK.; Faculty of Health, University of Sheffield, Sheffield, UK.; Adult Inherited Metabolic Diseases, Salford Care Organisation, Northern Care Alliance (NCA) NHS Foundation Trust, Salford, UK.; Divisions of Metabolism, University Children's Hospital, Zürich, Switzerland.; University College London Institute of Ophthalmology, University College London, London, UK.; Department of Pharmacology, University of Oxford, Oxford, UK.; Medical Biochemistry Department, University of Leiden, Leiden, the Netherlands.; Denali Therapeutics, South San Francisco, California, USA.; Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA.; Adult Inherited Metabolic Diseases, Salford Care Organisation, Northern Care Alliance (NCA) NHS Foundation Trust, Salford, UK.; Division of Cardiovascular Sciences, University of Manchester, Manchester, UK.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.